Officer Brian Lian Files Intent to Sell $7.69M in Viking Therapeutics Stock
VKTX sits 70% above its 52-week low of $18.92 on elevated volume (2.2× avg).
Summary
An officer at Viking Therapeutics, Brian Lian, has filed a Form 144 indicating an intent to sell approximately $7.69 million worth of common stock, representing a notable disposition of shares.
Key Events · Ownership and Investor Activity · VKTX
-
Officer Files Intent to Sell
Brian Lian, an officer of Viking Therapeutics, has filed a Form 144 indicating an intent to sell 233,409 shares of common stock.
-
Significant Proposed Sale Value
The proposed sale has an approximate market value of $7,692,133.64, representing a notable disposition of shares relative to the company's market capitalization.
-
Recent Insider Selling History
The filing also notes that Brian Lian previously sold 38,989 shares for gross proceeds of $1,364,923.01 within the past three months.
Analysis · VKTX · Life Sciences
The filing of a Form 144 by an officer, Brian Lian, to sell a significant amount of Viking Therapeutics stock (over $7.69 million) is an important event for investors. While Form 144 only indicates an intent to sell, the substantial value involved, especially from an insider, could be perceived negatively as it suggests a reduction in personal exposure to the company. Investors should monitor subsequent Form 4 filings to confirm the actual sale and assess any further insider selling trends.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VKTX was trading at $32.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $18.92 to $43.55. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.